TTR and amyloidosis: In 2018, patisiran, the first siRNA drug approved by the U.S. Food and Drug Administration (FDA), was found to target transthyretin (TTR) messenger RNA in the liver to fight hereditary transthyretin amyloidosis [15], highlighting the potential of RNAi-based therapeutics for the treatment of diseases.